Samira Zeynalova

CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP

Norbert Schmitz, Samira Zeynalova, Maike Nickelsen et al. · Journal of Clinical Oncology · 2016 · 445 citations

Medicine, Oncology, Chemotherapy +13

CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)

Volkmar Boehme, Norbert Schmitz, Samira Zeynalova et al. · Blood · 2009 · 307 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

Volkmar Boehme, Samira Zeynalova, Marita Kloess et al. · Annals of Oncology · 2006 · 279 citations · Full text

Medicine, Neurology, Oncology +16

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL

Carsten Müller, Niels Murawski, Martin H. J. Wiesen et al. · Blood · 2012 · 237 citations · Full text

Pharmacy, Hematology, Pharmacokinetics +16

Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

H. Stoecklein, Samira Zeynalova, German Ott et al. · Leukemia · 2008 · 175 citations

Medicine, Molecular Genetics, Oncology +15